Telix's Illuccix Receives Approvals in Europe and Denmark for Prostate Cancer Imaging
• Telix Pharmaceuticals' Illuccix receives European marketing authorization for prostate cancer imaging, following a positive decision via decentralized procedure.
• Illuccix is now approved in Denmark for detecting PSMA-positive lesions in adults with prostate cancer across multiple clinical settings.
• PSMA-PET imaging with Illuccix offers superior accuracy for staging primary disease and evaluating biochemical recurrence, replacing conventional methods.
• The approvals set the stage for commercial launches in Europe and Denmark, enhancing access to advanced prostate cancer diagnostics.
© Copyright 2025. All Rights Reserved by MedPath